Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemic
- 18 August 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Drug Safety
- Vol. 22 (2) , 165-174
Abstract
Pharmacovigilance (PV) activities were affected by COVID-19. Therefore, several health authorities around the world have issued guidelines and practices to ensure that PV activities are maintained ...Keywords
All Related Versions
This publication has 19 references indexed in Scilit:
- The Role of Pharmacovigilance and ISoP During the Global COVID-19 PandemicDrug Safety, 2020
- National pharmacovigilance programs in Arab countries: A quantitative assessment studyPharmacoepidemiology and Drug Safety, 2020
- Pharmacovigilance Systems in Arab Countries: Overview of 22 Arab CountriesDrug Safety, 2019
- Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiencesGlobalization and Health, 2018
- Current state of pharmacovigilance in the Arab and Eastern Mediterranean region: results of a 2015 surveyInternational Journal of Pharmacy Practice, 2017
- How to promote adverse drug reaction reports using information systems – a systematic review and meta-analysisBMC Medical Informatics and Decision Making, 2016
- Pharmacovigilance in resource-limited countriesExpert Review of Clinical Pharmacology, 2015
- The First Eastern Mediterranean Region/Arab Countries Meeting of PharmacovigilanceDrugs - Real World Outcomes, 2015
- Pharmacovigilance bolstered in the Arab worldThe Lancet, 2014
- Drug Safety in the Digital AgeNew England Journal of Medicine, 2014